California Tool Works: Assessing the Impact of Life Science Incubators and Accelerators
With the proliferation of types and business models in incubation and acceleration, a landscape survey commenced nearly a decade ago with innovation professionals running accelerators, incubators, corporate innovation teams, venture studios, and maker spaces. The benchmarking continues under the aus...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
ThinkBiotech LLC
2021
|
| Subjects: | |
| Online Access: | View Fulltext in Publisher |
| LEADER | 01872nam a2200397Ia 4500 | ||
|---|---|---|---|
| 001 | 10.5912-jcb977 | ||
| 008 | 220427s2021 CNT 000 0 und d | ||
| 020 | |a 14628732 (ISSN) | ||
| 245 | 1 | 0 | |a California Tool Works: Assessing the Impact of Life Science Incubators and Accelerators |
| 260 | 0 | |b ThinkBiotech LLC |c 2021 | |
| 856 | |z View Fulltext in Publisher |u https://doi.org/10.5912/jcb977 | ||
| 520 | 3 | |a With the proliferation of types and business models in incubation and acceleration, a landscape survey commenced nearly a decade ago with innovation professionals running accelerators, incubators, corporate innovation teams, venture studios, and maker spaces. The benchmarking continues under the auspices of the California Business Incubation Alliance. For this paper, a selected set of findings specific to biotechnology have been detailed, including best practices, success measures, outcomes, and economic impact. The perspective of entrepreneurs, innovation executives, investors, and the public sector have been taken into account throughout this exercise. © 2021 ThinkBiotech LLC. All rights reserved. | |
| 650 | 0 | 4 | |a Article |
| 650 | 0 | 4 | |a benchmarking |
| 650 | 0 | 4 | |a Best practices |
| 650 | 0 | 4 | |a biomedicine |
| 650 | 0 | 4 | |a Biotechnology |
| 650 | 0 | 4 | |a Business incubations |
| 650 | 0 | 4 | |a Business models |
| 650 | 0 | 4 | |a California |
| 650 | 0 | 4 | |a commercial phenomena |
| 650 | 0 | 4 | |a Corporate innovation |
| 650 | 0 | 4 | |a economic development |
| 650 | 0 | 4 | |a Economic impacts |
| 650 | 0 | 4 | |a health care availability |
| 650 | 0 | 4 | |a human |
| 650 | 0 | 4 | |a internet of things |
| 650 | 0 | 4 | |a Life-sciences |
| 650 | 0 | 4 | |a product development |
| 650 | 0 | 4 | |a public sector |
| 650 | 0 | 4 | |a Public sector |
| 650 | 0 | 4 | |a shared decision making |
| 650 | 0 | 4 | |a Success measure |
| 650 | 0 | 4 | |a velocity |
| 700 | 1 | |a Gardner, M. |e author | |
| 773 | |t Journal of Commercial Biotechnology | ||